Navigation Links
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Date:2/6/2012

879.42 Myeloma 7899.43 Nasopharyngeal Cancer 7929.44 Neuroendocrine Cancer (general) 7939.45 Neuroendocrine Cancer (pancreatic) 7949.46 Neurofibromatosis 7969.47 non-Hodgkin's Lymphoma 7979.48 Non-Small Cell Lung Cancer 7999.49 Oesophageal Cancer 8059.50 Oral Cancer 8079.51 Osteo Sarcoma 8089.52 Ovarian Cancer 8099.53 Pancreatic Cancer 8139.54 Peritoneal Cancer 8169.55 Prostate Cancer 8189.56 Radio/chemotherapy-induced Alopecia 8229.57 Radio/chemotherapy-induced Infection 8229.58 Renal Cancer 8239.59 Sarcoma (general) 8289.60 Small Cell Lung Cancer 8309.61 Soft Tissue Sarcoma 8339.62 Solid Tumor 8359.63 Squamous Cell Cancer 8399.64 Synovial Sarcoma 8409.65 T-cell Lymphoma 8419.66 Testicular Cancer 8429.67 Thyroid Cancer 8439.68 Unspecified 8459.69 Vaccine adjunct 8489.70 Waldenstrom's hypergammaglobulinemia 84810 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 84910.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 85310.2 Company Facts and Ranking 85510.3 Competitive Fall-Out Assessment 86110.4 Abbott 86410.5 Acceleron Pharma 87510.6 Access 87910.7 Active Biotech 88310.8 Adherex 88710.9 Advantagene 89510.10 Advaxis 90110.11 Advenchen 90510.12 Aeterna Zentaris 90910.13 Agennix 91610.14 Aida Pharmaceuticals 92010.15 Alnylam 92410.16 Ambit Biosciences 92810.17 Ambrilia Biopharma 93410.18 Amgen 93810.19 Amphora 94610.20 Angiogen 95010.21 Angiogenex 95410.22 Angstrom Pharmaceuticals 95810.23 Ansaris 96210.24 Antisoma 96610.25 Arana Therapeutics 97010.26 Ariad 97410.27 Arno Therapeutics 98410.28 ArQule 98810.29 Array BioPharma 99410.30 Astellas 99810.31 Astex Therapeutics 100410.32 AstraZeneca 100810.33 Attenuon 101610.34 Austrianova 102210.35 Bayer 102610.36 BioAlliance Pharma 103610.37 BioAxone 104110.38 Biocad 104510.39 Boehringer Ingelheim 105110.40 Bolder BioTechnology 105710.41 Bristol-Myers Squibb 106310.42 BTG 107510.43 Cancer Research Technology 108110.44
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
2. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
3. KellBenx Secures Exclusive Worldwide License With AdnaGen for Commercializing Patented Antibodies
4. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
5. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
6. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
7. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
8. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
9. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
(Date:5/22/2015)... --  InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the ... announced that its CGuard TM Embolic Prevention System reported ... Piotr Musialek , at the EuroPCR conference on ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Findings Include 80% SVR12 Rate with Nitazoxanide-Based Combination Therapy ... into Mechanism of Action of Nitazoxanide, MILAN, Italy, ... today announced that data from studies of,nitazoxanide in chronic ... presentations made at the 43rd Annual Meeting of the,European ...
... Award of a National Institutes of Health Small, ... Phase 2 Trial, HOUSTON, April 22 Agennix, ... placebo-controlled Phase 2 study,of oral talactoferrin alfa in patients ... talactoferrin in sepsis and is based on both the,mechanism ...
Cached Medicine Technology:Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 2Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 3Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 4Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 5Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 6Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 7Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 2Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 3Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 4Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis 5
(Date:5/25/2015)... Decora Preset 60 Minute Countdown Timer , a ... Hardware City.’ The product helps in automatically switching off any ... the related electronic device is automatically turned off after the ... said, “We are glad that this amazing product is now ... Timer Switch in just a few clicks. The product has ...
(Date:5/24/2015)... Michigan (PRWEB) May 24, 2015 ... them to take pressure measurements in patients’ bladder and ... doctor usually orders it if they have reported symptoms ... , Women’s Excellence in Bladder Control is ... unwanted urinary leakage or problems with overall control of ...
(Date:5/24/2015)... Indianapolis, Indiana (PRWEB) May 24, 2015 ... network service provider announces Midwest Telecom of America, Inc. ... , According to Cory Childs, IFN Enterprise Sales ... to service providers. “IFN’s fiber transport provides MTA ... Operations Center to their Tier 1 Internet and voice ...
(Date:5/23/2015)... 23, 2015 On May 13, Nithyananda ... a youngster's yogic power learned through meditation and initiation ... in Bangalore, India. , Yogamaatha, a nine-year-old girl from ... high profile professionals attending the 2015 Business Advocacy Summit ... -- blindfolded. , In a demonstration that lasted ...
(Date:5/23/2015)... Manufacturers are now required to produce water heaters ... Experts in the field agree that the regulation is aimed ... score is what miles per gallon is to your car. ... the minimum HSPF score has been raised to 8.2, technology ... north of 12. Indeed, the regulation was welcomed by environmentalist, ...
Breaking Medicine News(10 mins):Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... as Executive Vice President, Managing Director, NEW YORK, ... network, announced that Marcy Leger has joined the firm ... LM&P New,York, as a result of the tremendous growth ... President of Euro RSCG Life LM&P New,York and Chicago., ...
... NASA will release a,report on an astronaut and ... media teleconference to discuss the report at 2 ... an independent external committee,conduct a comprehensive review of ... NASA,s Johnson Space Center, Houston, began an internal,assessment ...
... Resources and National Association of Children of Alcoholics Offer ... Free Training Seminar for Clergy on January 30, 2008, ... and drug treatment agency and the National Association of ... others involved,in pastoral care with a free one-day training ...
... history, is determining factor, study finds , , TUESDAY, Jan. ... radiation treatment for fast-moving prostate cancer can save lives, ... have other serious medical problems, a new study shows. ... there definitely is a difference in outcome, depending on ...
... helps patients shed more pounds than dieting and exercise ... New research suggests that gastric lap-band surgery isn,t only for ... who aren,t severely fat. , Still, the surgery is extremely ... people with diabetes who need alternative ways to shed pounds, ...
... 22 STERIS Corporation,(NYSE: STE ) today announced ... dividend in the amount of $0.06 per common share. ... record at the close,of business on February 12, 2008., ... is to provide a healthier today and,safer tomorrow through ...
Cached Medicine News:Health News:Euro RSCG Life LM&P Announces Growth of Leadership Team 2Health News:Hormone Therapy Only Helps Some Older Men With Prostate Cancer 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 2Health News:Gastric Lap-Band Surgery Can Send Diabetes Into Remission 3Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3
... are becoming very popular only a few ... the pack. Explore why MediTalk is rapidly ... and practice administrators. An EMR designed by ... doctors see patients quickly and efficiently while ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
... Software developed a touchscreen EHR and is ... a user can choose to use a ... maintain eye contact while recording encounter results. ... EHR also runs on a pen tablet ...
Medicine Products: